Semaglutide for secondary cardiovascular prevention: An update that may have gone unnoticed – what NICE TA1152 means for primary care

NICE TA1152 establishes semaglutide 2.4 mg as a secondary cardiovascular-prevention treatment for adults with established cardiovascular disease and BMI ≥27 kg/m². Implementation will require primary care to distinguish cardiovascular prescribing from diabetes and weight-management pathways—and to integrate it without creating new barriers to treatment.

Semaglutide has travelled a long way from its original identity as a glucose-lowering medicine. Semaglutide is established in type 2 diabetes, and the 2026 update to NICE NG28 recommends subcutaneous semaglutide, up to 1 mg once weekly, as part of initial treatment for people with type 2 diabetes and established atherosclerotic cardiovascular disease. This recommendation is not dependent on exceeding a particular HbA1c or BMI threshold.

The 2.4 mg semaglutide preparation has a different dose and licence. Its role has primarily been associated with weight management, but NICE TA1152 now establishes a third use: reducing major adverse cardiovascular events in adults with established cardiovascular disease and a BMI of at least 27 kg/m². This is not diabetes or obesity guidance wearing a cardiology hat. It is a distinct secondary-prevention indication, supported principally by the SELECT cardiovascular-outcomes trial. Diabetes is not required, although the NICE recommendation does not exclude people who have it.

The appraisal is also timely. The Cardiovascular Disease Modern Service Framework calls for a more integrated cardiovascular–kidney–metabolic approach, earlier prevention and care delivered closer to home. TA1152 fits that direction of travel, but it also raises practical questions about patient identification, treatment sequencing, monitoring, capacity and equitable access, but ultimately asks us to consider holistic patient picture rather than siloed risk factor management.

Who qualifies and who does not?

The criteria: established cardiovascular disease, meaning a previous myocardial infarction, ischaemic or haemorrhagic stroke, or symptomatic peripheral arterial disease, plus a BMI of 27 kg/m² or above. Type 2 diabetes isn't required either way.

Treatment is semaglutide, titrated over 16 weeks to the cardiovascular maintenance dose of 2.4 mg once weekly, alongside a reduced-calorie diet and increased physical activity. The newer 7.2 mg semaglutide regimen relates to weight management only; it is not the TA1152 cardiovascular dose.

Semaglutide is added to standard secondary prevention rather than replacing it. Lipid lowering, blood-pressure management, appropriate antithrombotic treatment, smoking cessation and lifestyle support remain the foundations on which any additional reduction in residual risk is built.

The evidence: SELECT

The recommendation rests on SELECT, a trial of 17,604 adults with a BMI of 27 or above and established cardiovascular disease, none of them with diabetes. Semaglutide versus placebo, both on top of standard care, produced a 20% relative risk reduction in major adverse cardiovascular events (hazard ratio 0.80, 95% CI 0.72 to 0.90). Non-fatal MI dropped too (HR 0.72), and so did all-cause mortality (HR 0.81), although this result should be interpreted cautiously because the formal hierarchical testing sequence had already stopped at cardiovascular death.

The event curves separated relatively early, and later analyses suggest that weight loss alone may not fully explain the benefit. The mechanism nevertheless remains uncertain and is likely to reflect several effects, including changes in adiposity, inflammation, blood pressure, glycaemia and other metabolic pathways.

NICE's recommendation is broader than the population directly studied in SELECT. The trial excluded people with diabetes and those with an MI, stroke, unstable-angina admission or transient ischaemic attack within the preceding 60 days. NICE's committee concluded that the cost-effectiveness estimates were within the range normally considered an acceptable use of NHS resources.

One molecule, three recommended uses

The breadth of semaglutide's place in NICE guidance is easy to miss when each document is read in isolation.

• Diabetes and ASCVD - NG28: semaglutide, up to 1 mg once weekly, can form part of initial treatment for people with type 2 diabetes and established ASCVD. The recommendation is not conditional on a particular BMI or on HbA1c being above target.

• Secondary cardiovascular prevention - TA1152: semaglutide 2.4 mg once weekly is recommended for adults with established cardiovascular disease and BMI ≥27 kg/m², whether or not they have diabetes.

• Weight management - NG246 and TA875: semaglutide 2.4 mg sits within the overweight and obesity pathway, with its own eligibility criteria, service requirements, review rule and access restrictions due to the need of specialist weight-management service and two-year treatment limit.

A patient with type 2 diabetes, a previous MI and BMI 32 kg/m² may fit more than one pathway. The question is therefore not merely whether semaglutide should be considered, but which licensed product, dose and therapeutic objective best fit that person's needs. That decision must account for the indication being treated, the direct evidence base, glycaemic needs, weight-management needs, tolerability, local pathways and patient preference. The diabetes and cardiovascular-prevention semaglutide regimens should not be treated as interchangeable prescriptions simply because they contain the same molecule. This requires clinical judgement rather than a flowchart and can introduce a clinical conundrum.

There is precedent for this evolution. SGLT2 inhibitors began as glucose-lowering treatments before evidence established distinct roles in heart failure and chronic kidney disease, including in people without diabetes. Semaglutide is undergoing a comparable change in clinical identity: from diabetes treatment to weight-management medicine, renal-protection and now to a separate cardiovascular-prevention option.

Cardiovascular prevention, not simply weight management

Meeting the TA1152 criteria should trigger a cardiovascular-prevention conversation, not an isolated discussion about body weight. It should also prompt a comprehensive review of the foundations of secondary prevention. The SELECT trial had patients with well-controlled risk factors at baseline so we should ask ourselves some of the basics:

• Is blood pressure measured accurately and managed towards an individualised guideline target?

• Has lipid lowering been intensified appropriately, including combination treatment when needed, rather than prescribing a statin and assuming the job is finished?

• Is antiplatelet or anticoagulant treatment appropriate for the underlying indication?

• Have smoking and alcohol use been addressed rather than merely coded?

• If diabetes is present, are HbA1c, kidney risk and the wider treatment regimen being reviewed?

• Has the patient been offered meaningful, individualised support with diet, activity and lifestyle that extends beyond the stereotypical "you need to eat better and exercise more"?

This review should happen alongside consideration of semaglutide, not become an unofficial hurdle to receiving it. TA1152 does not require every other risk factor to be at target first. A person with BP 155/95 mmHg, lapses in statin adherence and an indication for semaglutide may need all three issues addressed concurrently. The objective is additive risk reduction, not a sequence in which one intervention must be completed before the next can begin.

Patient interest may be greater than it is for statins or antihypertensive treatment because semaglutide is publicly associated with weight loss. That makes transparent shared decision-making particularly important. The conversation should cover the cardiovascular indication, expected absolute benefit, long-term treatment, dose escalation, gastrointestinal adverse effects and the fact that semaglutide complements rather than substitutes for established secondary prevention.

The eligible population numbers may be large

Obesity in England rose from 26.3% of adults in 2019 to 30.3% by 2025, and overweight adds a great many more. A large chunk of every practice's cardiovascular secondary prevention register will meet the BMI threshold for TA1152 already. If you ran a search tomorrow, the eligible list could be uncomfortably long, and that's why population health thinking may have to replace a simple tick-box search.

There is currently no validated semaglutide-specific score that identifies who should be treated first like we saw with tirzepatide and weight management in TA1026, therefore, providers may need to develop their own phased implementation system. Recency or multiplicity of cardiovascular events, coexisting chronic kidney disease, heart failure or diabetes, frailty, treatment burden, likely tolerability and the person's preferences may reasonably inform sequencing. However, none of these replaces the actual TA1152 eligibility criteria.

Markers such as uACR, triglycerides and Lp(a), and conditions associated with chronic inflammation, can enrich a broader assessment of residual cardiovascular risk. They may uncover additional actions: kidney-protective treatment, more intensive lipid lowering or investigation of inherited risk. They are not prerequisites for TA1152, however, and an extended biomarker panel should not become a new barrier to semaglutide, but should instead be seen as complementary, helping to further reduce risk.

Not everyone who clears the BMI and CVD bar needs to be first in the queue. A patient with a recent MI, poorly controlled residual risk factors and a BMI of 34 is a different clinical priority to someone eight years post-stroke, well controlled on four secondary prevention drugs, with a BMI of 28 who's already stable.

A sensible population approach for this may be to start conversations with the highest-risk or most in-need patients first, the ones for whom this is likely to be additive benefit rather than a substitute for work that hasn't been done yet or is pending.

Duration, review and stopping treatment

TA1152 contains no fixed treatment duration and no weight-loss response rule. Cardiovascular prevention should be regarded as long-term treatment, subject to regular review of tolerability, safety, adherence, patient preference and the continuing balance of benefit and treatment burden.

Stopping rules borrowed from weight-management pathways should not be applied automatically. Failure to reach a weight-loss target does not demonstrate failure of cardiovascular protection, because weight loss is not the treatment endpoint under TA1152. Equally, 'long term' does not mean 'never review'. Unacceptable adverse effects, clinically concerning weight loss or frailty, pregnancy, pancreatitis or another safety issue, inability to tolerate an effective regimen, or a change in patient preference may all justify reassessment or discontinuation.

Patients should understand before starting that there may be no natural point at which treatment is considered complete. They should also know that continuing therapy remains a shared decision, not an irrevocable commitment.

What this means in the next primary-care review

Cardiovascular care has often been delivered through siloed conversations: blood pressure, cholesterol, smoking, glycaemia and kidney function, each with its own target and template. TA1152 does not sit neatly within one of those silos. It asks primary care to consider the person's overall cardiovascular risk and the interventions that reduce future events.

Semaglutide is not titrated against an LDL-C value or a blood-pressure reading. Its purpose is to reduce the probability of another cardiovascular event. That does not make numerical targets unimportant; it means reaching them is not necessarily the end of risk – residual risk remains. As with icosapent ethyl under TA805, semaglutide under TA1152 has eligibility criteria but no single marker that confirms the treatment is working. Some treatments are intensified to a measured target, while others are offered because outcome trials demonstrate additional protection in an eligible population.

This changes what "the patient is optimised" actually means. Blood pressure at target and LDL-C at target isn't the finish line if the finish line was always fewer cardiovascular events, not a set of numbers looking acceptable on a screen. It means the conversation with patients must shift too. Less "let's get your blood pressure down" or "let's sort your cholesterol," each one a closed loop that ends once a number looks fine. More "let's look at everything that's driving your risk of another heart attack or stroke, and work through what the evidence says actually helps." That's a bigger conversation, and it needs a review that treats BP, lipids, glycaemic control, weight, smoking and kidney function as one risk picture rather than boxes ticked in sequence.

A practical starting point is to search the CVD secondary-prevention registers and improve missing BMI coding. For potentially eligible patients, confirm the qualifying cardiovascular history, current BMI, contraindications and preferences; review BP, lipids, antithrombotic treatment, smoking, kidney function and, where relevant, diabetes; and address gaps in parallel. Most importantly, frame the consultation around preventing the next cardiovascular event, not around obtaining a weight-loss injection and not around adding another item to an already long medication list. TA1152 is most valuable when it becomes part of coherent secondary prevention rather than another isolated prescribing silo.

Summary

• A new secondary-prevention indication: NICE TA1152 recommends semaglutide 2.4 mg once weekly for adults with established cardiovascular disease and BMI ≥27 kg/m², whether they have diabetes or not.

• SELECT showed a 20% relative risk reduction in major cardiovascular events, and the benefit turned up before most of the weight loss did.

• One molecule now has three NICE pathways: semaglutide under NG28 treats type 2 diabetes with ASCVD; semaglutide 2.4 mg under TA1152 reduces secondary cardiovascular risk; and semaglutide under NG246/TA875 supports weight management. Each pathway has a different indication, dose and service framework.

• Semaglutide complements, not replaces, standard care: BP, lipid lowering, appropriate antithrombotic therapy, smoking cessation, kidney protection and lifestyle support should be reviewed alongside semaglutide rather than used as hurdles that must all be completed first.

• Implementation may need to be phased: Practices should identify eligible people from secondary-prevention registers. Additional markers such as uACR, triglycerides or Lp(a) can enrich risk assessment but are not TA1152 eligibility requirements.

• Treatment should be approached as long term: TA1152 has no fixed duration or weight-loss stopping rule. Review tolerability, safety, adherence, patient preference and treatment burden regularly, while framing the conversation around preventing the next cardiovascular event—not simply losing weight.

• Cardiovascular care is evolving towards a whole-person approach: The CVD Modern Service Framework promotes joined-up cardiovascular–kidney–metabolic care, with blood pressure, lipids, glycaemia, weight, smoking and kidney function considered as one overall risk picture rather than managed in separate clinical silos.

References

1. NICE. Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity. Technology appraisal guidance TA1152. Available at: https://www.nice.org.uk/guidance/ta1152

2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.

3. NICE. Type 2 diabetes in adults: management. NICE guideline NG28.

4. NICE. Summary of NICE guidance for GLP-1 receptor agonists and tirzepatide in adults. Available at: https://www.nice.org.uk/guidance/ng28/resources/summary-of-nice-guidance-for-glp1-receptor-agonists-and-tirzepatide-in-adults-pdf-15721582861

5. NICE. Obesity: identification, assessment and management of overweight and obesity. NICE guideline NG246.

6. NICE. Semaglutide for managing overweight and obesity. Technology appraisal guidance TA875. 2023. Available at: https://www.nice.org.uk/guidance/ta875

7. NICE. Tirzepatide for managing overweight and obesity. Technology appraisal guidance TA1026. Available at: https://www.nice.org.uk/guidance/ta1026

8. Department of Health and Social Care, NHS England. Cardiovascular disease modern service framework. Published 7 July 2026.

9. Baker C. Obesity statistics. House of Commons Library research briefing. Available at: https://commonslibrary.parliament.uk/research-briefings/sn03336/

10. NICE. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805). 2021.

11. Electronic Medicines Compendium. Semaglutide 2.4 mg FlexTouch: Summary of Product Characteristics. Available online.